Mandolin has raised $40M in funding to enhance access to life-saving therapies using AI agents. The investment was led by Greylock Partners and others, aimed at improving patient treatment efficiency.
Mandolin has raised $40M in funding to enhance access to life-saving therapies using AI agents. The investment was led by Greylock Partners and others, aimed at improving patient treatment efficiency.
06/25/25, 4:14 PM
Location
san franciscoMoney raised
$40 million
Industry
information technology
Investors
Guillermo Rauch, Jerry Yang, Sv Angel, Maverick, Signal Fire, Greylock Partners
Mandolin, an AI automation platform for specialty drug access, announced a $40 million funding round led by Greylock Partners, SignalFire, and others. This funding will help healthcare providers verify insurance coverage faster to ensure timely patient treatment. The platform is used by major infusion providers and health systems in the nation. Recent advancements in specialty therapies highlight the need for efficient processes in drug administration and insurance approvals.
Company Info
Location
2261 market st ste 86638
san francisco, california, united states
Additional Info
Mandolin is the leading AI automation platform for specialty drug access. The company’s AI agents act just like a best employee, completing tasks like reasoning about clinical policies, calling payers, parsing faxes and handwritten notes, and making decisions across entire workflows. Backed by Greylock, SignalFire, Maverick, and SV Angel, Mandolin works with the largest consolidated infusion providers, specialty and home infusion pharmacies, and health systems in the country.